AK158D1
/ Akesobio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 17, 2026
Akeso…announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA)
(PRNewswire)
- "The trial will assess the candidate in patients with advanced malignant solid tumors. AK158D1 is Akeso's fourth ADC to enter clinical development..."
New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1